Table 6.
Effectiveness of KSK and standard therapy according to vaccination status.
| Laboratory investigation | Complete vaccination |
No vaccination |
||
|---|---|---|---|---|
| Kabasura Median (IQR)/n (%) | Standard therapy Median (IQR)/n (%) | Kabasura Median (IQR)/n (%) | Standard therapy Median (IQR)/n (%) | |
| CRP Baseline | 5.5 (50.3) | 8.8 (92.4) | 3.2 (56.4) | 5.7 (43.2) |
| CRP Day 10 | 2.4 (17.5) | 3.4 (53.2) | 1.6 (21.6) | 2.9 (10.4) |
| Difference | −3.08 (42.1) | −6.1 (46.9) | −1.26 (36.1) | −3.1 (48.6) |
| IL6 Baseline | 12.2 (156.4) | 7.5 (125.8) | 10.6 (78.3) | 5 (161.5) |
| IL6 Day 10 | 3.4 (27.2) | 2.8 (19.6) | 2.15 (26) | 1.7 (30.7) |
| Difference | −7.9 (146.8) | −5.7 (126.6) | −6.15 (77.3) | −3.8 (157.5) |
| IgG Baseline | 1.59 (117.2) | 8.75 (240.3) | 2.85 (306.6) | 1.4 (54.1) |
| IgG Day 10 | 143 (376) | 58.6 (344.5) | 182.9 (409) | 158 (376.8) |
| Difference | 159 (460) | 106 (418) | 140.2 (316.2) | 46.2 (353) |
| RTPCR negative Day 5 | 9/29 (31%) | 7/24 (29.2%) | 6/22 (27.3%) | 7/25 (28%) |
| RTPCR negative Day 10 | 15/29 (51.7%) | 14/24 (58.3%) | 11/22 (50%) | 13/25 (52%) |